Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Parthasarathy Ranjarajan"'
Autor:
Amanda E. Brinker, Roy A. Jensen, John A. Taylor, Shrikant Anant, Scott Weir, Parthasarathy Ranjarajan, Michael Dalton, Michael Baltezor, Tammy Ham, William McCulloch, Benjamin L. Woolbright, Prabhu Ramamoorthy, Robyn Wood, Prasad Dandawate, Mehmet Tanol
Publikováno v:
Cancer Research. 80:6405-6405
Ciclopirox (CPX) is a FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in solid and hematologic malignancies. It's clinical utility as an anticancer agent, however, is limited by poor oral bioavailability, g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fb687f908a1061baaca8e45d7973124
https://doi.org/10.1158/1538-7445.am2020-6405
https://doi.org/10.1158/1538-7445.am2020-6405
Autor:
Michael Dalton, Michael Baltezor, John A. Taylor, Parthasarathy Ranjarajan, John L. Haslam, Kathy Heppert, Robyn Wood, Lian G. Rajewski, Roy A. Jensen, Amanda E. Brinker, William McCulloch, Shrikant Anant, Scott Weir, Greg Reed, Tammy Ham, Prabhu Ramamoorthy, Michael J. McKenna, Karl Schorno
Publikováno v:
Journal of Clinical Oncology. 36:e14576-e14576
e14576Background: Ciclopirox (CPX) is an antifungal agent contained in a number of FDA-approved topical drug products. CPX possesses anticancer activity in a number of in vitro and in vivo preclini...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d1b7f6361667b896609cc390062329a
https://doi.org/10.1200/jco.2018.36.15_suppl.e14576
https://doi.org/10.1200/jco.2018.36.15_suppl.e14576